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1. Introduction 
Glucocorticoids are known as vitamin D antagonists. 
Cortisol is used in the treatment of hypercalcemia due 
to vitamin D intoxication [l] , sarcoidosis [2] or idio- 
pathic hypercalcemia of infancy [3]. 
Plasma calcium homeostasis is controlled by the 
interaction of the intestine, the kidney and the bone. 
These tissues are also thought to be target organs for 
vitamin D action, and the functional form of the 
vitamin in these sites is believed to be the dihydroxyl- 
ated derivative, 1,25(OH)zD3*. This compound is 
produced from vitamin D by C-25 hydroxylation in 
the liver, followed by C-l hydroxylation in the kidney. 
When 1 ,25(OH)*D3 interacts with intestinal or kidney 
cells, a specific CaBP+ is formed [4-61, which is 
believed to be involved in the process of calcium 
transport. 
Animal studies have shown that glucocorticoids 
are linked with decreased serum calcium concentration 
and decreased intestinal transport and absorption of 
calcium [7,8] . The present study was undertaken in 
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order to establish whether the hypocalcenic effect of 
glucocorticoids is mediated via an effect on the 
metabolism of vitamin D, and the subsequent biological 
expression of the vitamin in the form of CaBP. 
It was established, that cortisol treatment in rats is 
associated with decreased accumulation of 1 ,25(OH)2D, 
in both intestinal mucosa cells and kidney cells, with 
subsequent decrease in the concentration of the 
vitamin D-dependent intestinal CaBP. 
2. Experimental 
2.1. Animals 
Young male rats (Wistar) weighing 25-30 g were 
maintained for four weeks on a vitamin D-deficient 
diet [9] , modified for rats as previously described 
[IO] . At the end of this depletion period a four-week 
repletion period with radioactively labelled cholecal- 
ciferol started while the rats were being fed the same 
vitamin D-deficient diet. Every five to seven days 
during this period, each rat received a subcutaneous 
injection of 0.75 c(g [ 1 ,2-3H, 4-‘4C]cholecalcifero1 
dissolved in 0.1 ml propylene glycol. At the end 
of the repletion period the rats were divided into two 
groups, and for an additional 8 days were injected 
daily, respectively with: (a) propyleneglycol; (b) 
cortisol. Two days after the last injection the rats 
were killed, and tissues were taken for analysis. 
115 
Volume 82, number 1 FEBS LETTERS October 1977 
2.2. Analysis of the metabolites of cholecalciferol 
After killing, the scraped mucosa from the proximal 
12 cm of the small intestine and the kidneys of six rats 
from each group were removed weighed, minced, 
pooled and extracted for lipids [ 111. The lipid extracts 
were analyzed for cholecalciferol metabolites using 
thin-layer chromatography (t.1.c.) [ 121. The relative 
amount of 1 .25(OH)zDJ in the polar peaks eluted from 
the t.1.c. plates was calculated from the 3H/‘4C specific 
radioactivity ratios [ 131 . 
2.3. Analysis of intestinal CaBP 
Rats of comparable groups, which were injected 
with non-radioactive labelled cholecalciferol were 
killed, and the proximal 12 cm of the small intestine 
were removed. The mucosa of six such segments for 
each group was scraped, pooled, harvested and pro- 
cessed for analysis of CaBP content as previously 
described [ 141. 
2.4. Materials and doses 
[ 1 ,2-3H] cholecalciferol (spec. radioactivity 12.6 
Ci/mmol) and [4-14C] cholecalciferol (spec. radio- 
activity 32.3 Ci/mol) were obtained from the Radio- 
chemical Centre, Amersham, Bucks, England. [l ,2-3H, 
4-14C] Cholecalciferol was prepared by mixing the two 
single-labelled preparations so as to give a ‘H/14C ratio 
of approx. 5.0. Cortisol (A4-pregnen-1 l/3,17&, 21-triol- 
3, 20-dione) was obtained from Sigma Chemical, 
St. Louis, MO. USA. Each rat received a daily subcuta- 
neous injection of 1 mg cortisol, dissolved in 0.1 ml 
propylene-glycol. 
2.5. Measurement of radioactivity 
All radioactivity measurements were carried out in 
a Packard TriCarb automatic counter. Quenching was 
corrected for by the automatic external standardiza- 
tion and correlation curves for combined 14C and 3H. 
3. Results 
Since chemical methods for measuring cholecal- 
ciferol metabolites are not readily available, the 
procedure of long-term administration of double- 
labelled radioactive cholecalciferol to rats employed 
in the present study, enabled the measurement of all 
the metabolites of cholecalciferol in target tissues for 
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vitamin D action. Under these conditions, cortisol 
treatment was found to result in decreased accumula- 
tion of 1 .25(OH)*D3 in intestinal mucosa cells (fig.1) 
and in kidney cells (fig.2). In both tissues the reduced 
levels of 1 ,25(OH)2D3 in the cells which were obtained 
from the cortisol treated rats was found to be accom- 
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Fig.1. The distribution of cholecalciferol and its metabolites 
in intestinal mucosa cells of rats treated with cortisol. For 
experimental details, see sections 2.1 and 2.2. (1.) Polar meta- 
bolites; (2) 1,25(OH),D,; (3) 24,25(OH),D,; (4) 25(OH)D,; 
(5) Vitamin D,. 
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Fig.2. The distribution of cholecalciferol and its metabolites 
in kidney cells of rats treated with cortisol. For experimental 
details, see sections 2.1 and 2.2. (1) Polar metabolites; (2) 
1,25(OH),D,; (3) 24,25(0H),D,; (4) 25(OH)D,. (5) 
Vitamin D, and vitamin Da-esters. 
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Table 1 
The effect of cortisol treatment on the concentration of intestinal CaBP 
Treatment CaBP 
(?a cpm bound/g tissue) 
% Control 
Propylene-glycol (control) 32.204 100 
Cortisol 25.450 19 
For experimental details see section 2.3 
panied by increased accumulation of 24, 25 (OH)sDs, 
a metabolite the production of which by the kidney is 
known to be inversely related to the production of 
1,25(OH),Ds [ 151. As shown in table 1, the reduced 
levels of 1 ,25(OH)sD3 in the intestinal mucosa cells 
obtained from rats treated with cortisol, was associated 
with a noticeable fall in the concentration of CaBP. 
4. Discussion 
The presented data on the effect of cortisol treat- 
ment on vitamin D metabolism and action, provides 
for the first time a biochemical basis upon which the 
well known hypocalcemic effect of glucocorticoids 
can be explained. 
As shown, chronic administration of cortisol to 
rats, similarly to the manner in which this steroid is 
used clinically, leads to a decrease in the concentra- 
tion of 1,25(OH)sDs in intestinal mucosa cells and 
kidney cells, and in the intestine this decrease was 
found to be associated with reduced levels of CaBP. 
Since the 1,25(OH)sDs dependent CaBP of both 
intestine and kidney is believed to be involved in the 
process of calcium absorption and calcium reabsorp- 
tion, respectively, the reduced levels of this protein 
as a consequence of the reduced accumulation of 
1,25(OH)sDa due to cortisol treatment, will result 
in a net hypocalcemic effect in the intact animal. The 
mechanism however, by which glucorticoids affect the 
accumulation of 1,25(OH)sDa in the target cells, still 
remains to be established. It is proposed that gluco- 
corticoids in chronic administration, compete with 
1,25(OH)sDs on the receptor sites in the target cells, 
thus displacing and preventing the interaction of 
1,25(OH)sDs with its functional binding sites. The 
possibility that the decreased accumulation of 
1,25(OH)sDs in the target cells in response to cortisol 
treatment is due to decreased production of 
1,25(OH)aDs was ruled out. Spanos et al. [ 161 have 
shown recently that chronic administration of cortisol 
to chicks leads to a profound stimulating effect on the 
activity of the renal 1-hydroxylase, when measured in 
vitro. 
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